Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Weibo Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.72 (market cap $5.07B), while Weibo Corp trades at $7.75 (market cap $1.93B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.6× Weibo Corp's market cap, and Weibo Corp pays a 7.75% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WB | |
|---|---|---|
Market Cap | $5.07B | $1.93B |
Sector | Health | Media |
52-Week High | $29.41 | $12.83 |
52-Week Low | $20.06 | $7.20 |
Enterprise Value | $4.19B | $1.20B |
Dividend Yield | — | 7.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
Weibo (WB) trades at $7.98, up 0.5% with neutral technical signals. The stock shows compelling valuation metrics including a P/E of 5.5 and P/B of 0.5, trading below balance sheet value. Recent quarters show earnings misses but strong profitability with 21.15% net margin. Cash flow trends improved in 2025 with $408M net inflow, while revenue remains stable at $1.76B.
WB presents value opportunity with deep discount to fundamentals, though competitive pressures and recent earnings misses warrant caution. Analyst consensus leans bullish with 45% buy ratings, but structural challenges in user engagement and AI monetization create headwinds. The 8% dividend yield provides downside protection while investors await growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
